A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Brainstorm Cell Therapeutics
  • Most Recent Events

    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
    • 07 Feb 2018 According to a Brainstorm Cell therapeutics media release, two scientific posters from this phase 2 study study will be presented as platform presentations at the American Academy of Neurology (AAN) Annual Meeting.
    • 29 Nov 2017 According to a Brainstorm Cell therapeutics media release, data from this trial will be presented at the 28th International Symposium on ALS/MND 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top